These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9228168)

  • 1. Behavior of Na131I and meta(131I) iodobenzylguanidine (MIBG) in municipal sewerage.
    Fenner FD; Martin JE
    Health Phys; 1997 Aug; 73(2):333-9. PubMed ID: 9228168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactivity in municipal sewage and sludge.
    Martin JE; Fenner FD
    Public Health Rep; 1997; 112(4):308-16; discussion 317-8. PubMed ID: 9258296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid discharges from patients undergoing 131I treatments.
    Barquero R; Basurto F; Nuñez C; Esteban R
    J Environ Radioact; 2008 Oct; 99(10):1530-4. PubMed ID: 18243440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to assessment and management of the impact from medical liquid radioactive waste.
    Sundell-Bergman S; de la Cruz I; Avila R; Hasselblad S
    J Environ Radioact; 2008 Oct; 99(10):1572-7. PubMed ID: 18242799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medically-derived 131I in municipal sewage effluent.
    Rose PS; Swanson RL; Cochran JK
    Water Res; 2012 Nov; 46(17):5663-5671. PubMed ID: 22925394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
    Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
    J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of delay tanks in the management of radioactive waste from thyroid therapy.
    Goddard C
    Nucl Med Commun; 1999 Jan; 20(1):85-94. PubMed ID: 9949417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
    Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
    Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine.
    Edeling CJ; Büchler Frederiksen P; Kamper J; Jeppesen P
    Nuklearmedizin; 1986 Oct; 25(5):172-5. PubMed ID: 3797256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
    Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
    Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients.
    Cui S; Jiao L; Tan J; Zhang G; Zhang H; Long W; Fan S; Zhang W
    Health Phys; 2014 Mar; 106(3):365-9. PubMed ID: 25208013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulating gaseous 131I distribution in a silver zeolite cartridge using sodium iodide solution.
    Wang WH; Matthews KL
    Health Phys; 2006 May; 90(5 Suppl):S73-9. PubMed ID: 16607172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion.
    Wafelman AR; Hoefnagel CA; Maes RA; Beijnen JH
    Nuklearmedizin; 1996 Aug; 35(4):122-5. PubMed ID: 8784866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma.
    Mangner TJ; Tobes MC; Wieland DW; Sisson JC; Shapiro B
    J Nucl Med; 1986 Jan; 27(1):37-44. PubMed ID: 3941363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.
    Hoefnagel CA; Voûte PA; de Kraker J; Marcuse HR
    Diagn Imaging Clin Med; 1985; 54(1):21-7. PubMed ID: 3918823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin.
    Mastrangelo R; Tornesello A; Riccardi R; Lasorella A; Mastrangelo S; Mancini A; Rufini V; Troncone L
    Eur J Cancer; 1995; 31A(4):606-11. PubMed ID: 7576979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepant salivary gland response after radioiodine and MIBG therapies.
    Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
    Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
    Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
    Weber W; Weber J; Senekowitsch-Schmidtke R
    Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
    O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
    Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.